Justin Z. Lee

Justin Z. Lee

Auto-generated profile, based on publicly available information

Justin Z. Lee

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Oh, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Heart Rhythm
Verified
Journal Article
Closed access
JLJustin Z. Lee
Justin Z. Lee
MMMonil Majmundar
Monil Majmundar
AKAshish Kumar
Ashish Kumar
STSamarthkumar Thakkar
Samarthkumar Thakkar
HPHarsh P. Patel
Harsh P. Patel
ADAbhishek J. Deshmukh
Abhishek J. Deshmukh

20 January 2018 in Open Heart
Verified
Journal Article
Open access
PDF file
JLJustin Z Lee
Justin Z Lee
SLSee-Wei Low
See-Wei Low
APAhmed K Pasha
Ahmed K Pasha
CHCarol L Howe
Carol L Howe
KLKwan S Lee
Kwan S Lee
PSPrakash G Suryanarayana
Prakash G Suryanarayana
Background Accurate determination of right ventricular ejection fraction (RVEF) is challenging because of the unique geometry of the right ventricle. Tricuspidannular plane systolic excursion (TAPSE) and fractional area change (FAC) are commonly used echocardiographic quantitative estimates of RV function. Cardiac MRI (CMRI) has emerged as the gold standard for assessment of RVEF. We sought to summarise the available data on correlation of TAPSE and FAC with CMRI-derived RVEF and to compare their accuracy. Methods We searched PubMed, EMBASE, Web of Science, CINAHL, ClinicalTrials.gov and the Cochrane Library databases for studies that assessed the correlation of TAPSE or FAC with CMRI-derived RVEF. Data from each study selected were pooled and analysed to compare the correlation coefficient of TAPSE and FAC with CMRI-derived RVEF. Subgroup analysis was performed on patients with pulmonary hypertension. Results Analysis of data from 17 studies with a total of 1280 patients revealed that FAC had a higher correlation with CMRI-derived RVEF compared with TAPSE (0.56vs0.40, P=0.018). In patients with pulmonary hypertension, there was no statistical difference in the mean correlation coefficient of FAC and TAPSE to CMR (0.57vs0.46, P=0.16). Conclusions FAC provides a more accurate estimate of RV systolic function (RVSF) compared with TAPSE. Adoption of FAC as a routine tool for the assessment of RVSF should be considered, especially since it is also an independent predictor of morbidity and mortality. Further studies will be needed to compare other methods of echocardiographic measurement of RV function.

31 October 2022 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
JLJustin Z. Lee
Justin Z. Lee
MTMin-Choon Tan
Min-Choon Tan
SKSuganya Karikalan
Suganya Karikalan
ADAbhishek J. Deshmukh
Abhishek J. Deshmukh
KSKomandoor Srivathsan
Komandoor Srivathsan
SMSiva K. Mulpuru
Siva K. Mulpuru

2 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MTMin Choon Tan
Min Choon Tan
YYYong Hao Yeo
Yong Hao Yeo
NMNoreen Mirza
Noreen Mirza
BSBoon Jian San
Boon Jian San
JTJian Liang Tan
Jian Liang Tan
AUAndrea M Cooper Medical School of Rowan University
Andrea M Cooper Medical School of Rowan University
Background: Despite significant cardiac involvement in sarcoidosis, real‐world data on death due to cardiovascular disease among patients with sarcoidosis is not well established. Methods and Results: We queried the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research database for data on patients with sarcoidosis aged ≥25 years from 1999 to 2020. Diseases of the circulatory system except ischemic heart disease were listed as the underlying cause of death, and sarcoidosis was stated as a contributing cause of death. We calculated age‐adjusted mortality rate (AAMR) per 1 million individuals and determined the trends over time by estimating the annual percentage change using the Joinpoint Regression Program. Subgroup analyses were performed on the basis of demographic and geographic factors. In the 22‐year study period, 3301 cardiovascular deaths with comorbid sarcoidosis were identified. The AAMR from cardiovascular deaths with comorbid sarcoidosis increased from 0.53 (95% CI, 0.43–0.65) per 1 million individuals in 1999 to 0.87 (95% CI, 0.75–0.98) per 1 million individuals in 2020. Overall, women recorded a higher AAMR compared with men (0.77 [95% CI, 0.74–0.81] versus 0.58 [95% CI, 0.55–0.62]). People with Black ancestry had higher AAMR than people with White ancestry (3.23 [95% CI, 3.07–3.39] versus 0.39 [95% CI, 0.37–0.41]). A higher percentage of death was seen in the age groups of 55 to 64 years in men (23.11%) and women (21.81%), respectively. In terms of US census regions, the South region has the highest AAMR from cardiovascular deaths with comorbid sarcoidosis compared with other regions (0.78 [95% CI, 0.74–0.82]). Conclusions: The increase of AAMR from cardiovascular deaths with comorbid sarcoidosis and higher cardiovascular mortality rates among adults aged 55 to 64 years highlight the importance of early screening for cardiovascular diseases among patients with sarcoidosis.

4 March 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
HPHoang Nhat Pham
Hoang Nhat Pham
RIRamzi Ibrahim
Ramzi Ibrahim
ESEnkhtsogt Sainbayar
Enkhtsogt Sainbayar
AOApril Olson
April Olson
ASAmitoj Singh
Amitoj Singh
MMMamas A. Mamas
Mamas A. Mamas
Background: Hyperlipidemia is a major cardiovascular disease (CVD) risk factor, but there are limited data on its mortality trends in CVD over time. We assessed annual hyperlipidemia‐related CVD mortality trends in the United States, including the COVID‐19 pandemic's impact. Methods and Results: Mortality data were obtained from the Centers for Disease Control and Prevention repository between 1999 and 2020 among patients ≥15 years old, using International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes for hyperlipidemia (E78.0–E78.5) and CVD (I00–I99). Age‐adjusted mortality rates (AAMRs) per 1 000 000 population were standardized to the 2000 US population. Log‐linear regression models were used to evaluate mortality shifts. Average annual percentage change from 1999 to 2019 was used to project 2020 AAMRs, estimating pandemic‐attributed excess deaths. From 1999 to 2020, 483 155 hyperlipidemia‐related CVD deaths occurred. Despite a general CVD mortality decline, hyperlipidemia‐related CVD AAMRs rose from 36.33 in 1999 to 99.77 in 2019. Ischemic heart diseases (AAMR 49.39) were the leading cause, whereas hypertension had the highest mortality increase (average annual percentage change +10.23%). Mortality rates were higher in men (AAMR 104.87) and non‐Hispanic (AAMR 82.49), and rural populations (AAMR 89.98). Highest mortality was observed in Black populations (AAMR 84.35), those ≥75 years old (AAMR 646.45), and Western US regions (AAMR 96.88). During the first pandemic year, deaths exceeded projections by 10.55%, with notable increases among ages 35 to 75 (14.23%), Hispanic (17.96%), Black (14.82%), and urban (11.68%) groups. Conclusions: Hyperlipidemia‐related CVD mortality has risen over the past 2 decades, further heightened by the COVID‐19 pandemic, with higher impact on men, Black Americans, the older population, and rural residents. Further study is needed to understand contributing factors and mitigate disparities.

1 November 2018 in Heart Rhythm
Verified
Journal Article
Closed access
JLJustin Z. Lee
Justin Z. Lee
PAPradyumna Agasthi
Pradyumna Agasthi
APAhmed K. Pasha
Ahmed K. Pasha
CTClaudia Tarin
Claudia Tarin
ATAndrew S. Tseng
Andrew S. Tseng
SMSiva K. Mulpuru
Siva K. Mulpuru